Good morning, everybody, and welcome to Terveystalo's Q3 results call and webcast. My name is Kati Kaksonen. I'm responsible for Investor Relations and Sustainability here at Terveystalo. As usual, we'll go through the result highlights with our CEO, Ville Iho, and our CFO, Juuso Pajunen. After the presentation, you will have a chance to ask questions. We'll take the questions from the phone lines as well as through the webcast after the presentation. Without further ado, over to you, Ville.
Thank you, Kati, and good morning from my behalf. Let's dive directly into Q3 highlights. As you can see from the numbers, this quarter 3 was a quarter of margin improvement amid revenue headwind. The EBIT, adjusted EBIT margin, developed positively. Very strong operating cash flow, EPS developing positively as expected. Very high NPS , ticking all-time highs all the time. With the decline of some 5% top line, adjusted EBIT in absolute terms slightly down. Double-clicking into different P&Ls and their role in the business, how they are contributing and continue contributing in the future. Starting from Sweden, just as a reminder, Sweden is in a phase still of turnaround. We have been adamant in the fact that we continue focusing only on turnaround and profitability improvement. Our Sweden team is getting the results. The underlying efficiency is continuously improving. The results continue to improve.
The market being fairly muted at this stage still. We are not making proper profits yet, but looking at next year, volume development looks positive and we start making results, and then it's time to focus on growth. Portfolio businesses, quite the same story. The profitability turnaround has for large parts happened. Some minor fixes in smaller businesses, but the bigger businesses are doing fine and developing positively. Now it's time to grow, and we are eyeing specifically in two different segments. As we have said before, dental and then opening public market. Healthcare Services, our biggest business, margin on a very, very high level, really strong, starting from a very strong position. Now our eyes and focus turn into volume growth, and we continue to boost that one with selective specialties driven M&A, and then investments in digital delivery and capabilities.
Further double-clicking into the strategic agenda. As I said, Sweden, profitability improvement program [GAMA], almost done and dusted, efficiency in all-time high level. Now looking at organic and potentially inorganic growth there on a solid base. Portfolio businesses, as I said, profitability improvement done and dusted. Now organic growth in dental and also inorganic growth in dental, and public partnership being relevant in the opening market when healthcare counties are actually starting buying, where we have seen positive signs already. Inside Healthcare Services, we are seeing very strong development in our consumer-driven businesses. We continue boosting that one, Kela 65, being a prime example of our sort of positive drive. Also in the insurance business, our position continues to be strong and developing nicely. Out of pocket in a good place and developing positively against the low morbidity.
We have reorganized our operations and our delivery model so that there's clearly a separate brick and mortar delivery through our Healthcare Services or hospital network. Now forcefully and decisively scaling up Digital Health 10x, where we are eyeing major leaps in efficiency in transactions, more intellect in our patient and customer steering, and finally truly scaling up truly digital healthcare services, text-based services, nurse services, and in the very near future also AI-supported health services. Among all of the positive developments, the challenge currently, which we'll further discuss, is in Occupational Health care. We know exactly where we are. We know how to turn around the negative development. There we have a program called VALTTI, led by new SVP of Occupational Healthcare, Corporate Health, Laura Karotie. That one will be discussed in more detail.
All in all, agenda very clear, sort of 9/10 , moving very fast to the positive territory. More focus needed for Occupational Health care, which will be fixed. Looking at the volume development and our view on markets in the near term, next 12 months, starting from the smallest. Sweden, as we have communicated many times, the market has been very soft. Swedish economy has driven the demand for Occupational Healthcare Services very low. Now looking forward, both the market seems to be picking up. Sweden's economy is doing better next year. More importantly, looking at our internal view on the sales funnel, commercial activities, sales funnel looks positive. When we are able to, during next year, pour more volume on higher operating leverage, of course, then we will start making money. Portfolio businesses, public business, as we all know, has been very, very slow in buying.
Healthcare counties are only sort of picking up the buying activities. What we see in large tenders and also in smaller tenders is increased activity. Looking at the next 12 months, we see the market developing positively. Same goes with the consumer business. It has been fairly muted due to low confidence of consumers. We have seen already some positive signs, specifically in the dental services, which typically is the most sensitive for consumer behavior. We expect the positive drive and vibe to continue for the next 12 months. In public business, when we jump over to Healthcare Services, in public services produced by Healthcare Services units, it has gone down and it has brought or contributed to lower volumes in Healthcare Services. We see that one bottoming out and the next 12 months should be more positive.
Consumer business, even though our own position has been strengthening, has been fairly flat due to low morbidity. With the sort of normalized view on that one, our strong drive in Kela 65 and insurance business, we see that one developing positively also going forward. Insurance business, equally, it has actually been the growth driver inside Healthcare Services, continues to be so. A number of insured persons in Finland continues to slightly slowly pick up and use of services is on a high level. Occupational Health care, finally, so we'll double-click on the development, what has contributed to lower volumes in Q3. Very shortly, it's a number of connected employees, sort of thinner scopes in the agreements by the corporate clients. Inside those agreement scopes, lower use of services. All of these are slightly negative from our business point of view. It's been negative.
It's going to stabilize, specifically the number of connected employees will not be sort of turned around in one quarter. We'll turn that one around, but it will take a couple of quarters to get to, again, to all-time highs. If we dive deeper into this phenomenon, as you can see, and it's good to remember the phases that we have seen in the development over the last couple of years and quarters. In 2022 and 2023, in a number of connected employees, we were pushing all-time highs. At the same time, as you remember, the profitability of this business was really, really low. We struggled with the low contribution to the rest of the business and hence the Alpha Program. With the Alpha Program, we totally turned around the profitability of not only Occupational Health care, but the company.
With that one, of course, some of the less profitable agreements went out. Now we see also some unintended tail effects of the Alpha period. Now what we are doing is, of course, we are rebalancing products, pricing, offering, and it's not going to be either or, it's going to be both, so both profitability and volumes. Occupational Healthcare, as I said, is the biggest focus area in our agenda currently. It will be turned around with our program. It's a comprehensive exercise of renewing, partly even transforming sales and account management, our product offering to become more relevant and according to expectations by ever-demanding customers. Finally, digital front door renewal, which we now can accelerate and fast-track with our MedHelp joint venture. Our customers will see tangible results already from Q1 onwards on this area.
A positive thing, very, very positive thing in our portfolio is consumer side, so combined insurance, Kela 65 out-of-pocket area. Our brand is doing fine, and that's, of course, one of the basic building blocks for boosting this business. We are the most preferred brand when we look at brand preference development. We have been so, but now we are all-time high. Also, in top of mind, the company, healthcare services company that Finnish consumers think about when they wake up in the morning, that's now Terveystalo for the first time. That itself gives a very solid base for further improvement in this business. We have invested heavily in the services. We have invested heavily in digital engagement with our consumer customers. We have invested in Kela 65, and in that particular new segment, we are a clear leader in that developing market.
Finally, Juuso will explain in detail the strength of our finances, the profitability, cash flow, and balance sheet. We continue increasing our investments in our digital capabilities. It's an ever-increasing value driver in our business model. We have some key focus points and developments in that digital ecosystem. For the professionals, we have launched the Ella user interface and digital front door, and continue scaling that one up. That's going to bring tangible efficiency improvements during next year in our sort of traditional brick-and-mortar appointment activities. For individual care, looking from a customer's point of view, as I said, it's very much in the core of our 10x agenda. We are making leaps in efficiency in transactions related to our incoming traffic and customer contacts. We are going to further improve the leading capabilities that we today already have in patient steering and customer steering.
Finally, we'll make efficiency leaps in text-based appointments, text-based digital appointments, nurse services, and introduce first AI-supported health services in the very near future. In occupational health, as I said already, we are now in a very good position to migrate our occupational health capabilities, digital capabilities, into a new MedHelp environment. It's best-in-class in Europe, and our customers, as I said, they will see tangible results and a fully new view and sort of better control on their own people, own organization, sick leaves, workability, starting from Q1 next year when we start deploying a new system to first customers. All in all, we are in this digital journey in a very strong, very good place. Our architecture is where it should be.
Our initiatives, projects create value, not in years, but rather in months, and we are confident in investing more and getting more yield out of the digital engine. With that one, over to you, Juuso.
Thank you, Ville. Good morning all. I'm Juuso Pajunen, CFO of Terveystalo, and let's talk about the financial performance in the third quarter. First of all, if we look at the whole group, we have a positive margin development continued despite the revenue headwinds. This was in relative terms the second best Q3 during the group's history, and the best one was during the COVID times. What I want to highlight is that our efficiency is in place, our machine is ticking. Also, having said that, we do know that we can't be happy on the growth and especially the revenue development when it comes to occupational healthcare. If we look at the big picture, portfolios in Sweden improve both in relative and absolute profitability, while they are still facing anticipated negative growth.
Portfolios in the outsourcing businesses in Sweden are still coming from the efficiency hunt and now going for the growth mode. With Healthcare Services, we have the strong margin, but the headwinds in the occupational health and the morbidity have been pushing the growth negative, like Ville also explained a bit on the occupational health part. If we look first on the Healthcare Services, I will double-click in the next slide on the growth, especially when it comes to visit growth. Let's park that question. All in all, the performance when it comes to the relative profitability, it was really solid. We had the decline in revenues, headwind in the markets, and despite those, we were able through solid cost control and our flexible operating model to keep our profitability in a good place, especially remembering that this is the low season Q3.
For the growth, we have a strong plan. In the longer perspective, I still remind you that the megatrends will continue to support our long-term outlook when it comes to the growth. Let's see the visits. Let's address the elephant in the room. Basically, we can split our visits growth. Now we are talking about volume. We can split it into different types of buckets. First of all, we have the morbidity. That one is basically seasonal. We have no control over that one. We had plenty fewer visits compared to the previous year. This is part of normal seasonal variation, and it changes annually. If we go into the Occupational Healthcare, we have different factors behind the decline. We have basically macro-driven components. The general employment in Finland is lower than earlier, and we have a sluggish economy. That one also impacts the employers' behavior.
Basically, they are implementing cost reduction initiatives due to their own economic pressures and push. That one impacts our demand also. A concrete example of that would be narrowing down the contract scopes on what they offer to their employees. We have the third component, which goes more into what we have done ourselves. As Ville explained, how our profit improvement program has been progressing and how despite having a very high amount of connected employees, our occupational health business was not super profitable. Now we have a very efficient machine, profitable business, and we need to load further volume on that one and get the benefit of the operating leverage. For that part, we have a solid, strong program ongoing, like Ville mentioned, the name is VALTTI.
We are confident that by implementing that program, we will address the weaknesses we have had, and we would expect to see growth in the number of connected employees in the coming year. In the public sector, especially the capacity sales, which is a minor part in the Healthcare Services segment, it is at a very low level due to the well-being county setups and all of that. Now we have seen that the sales pipeline is opening up and the market is little by little finding its form. We have the positive momentum, Kela 65 consumer insurance market, where we have been growing and we have been able to capture positive momentum. That one we will obviously continue pushing. The experiences from Kela 65 are very positive from the patient perspective and also from our perspective.
With all of this, there are various factors impacting our growth, and we will address especially the occupational health part decisively going forward. If we go into the portfolio businesses, we have clear improvement in profitability. We have been able to improve the EBIT margins continuously, 2.2 percentage points up compared to the previous year. We have the momentum in especially public sector business outsourcing. We have been guiding you that it will most likely decline EUR 30 million this year, and we are on that trend, on that pattern, and continuing on that. On staffing, we started to have revenue headwinds during roughly a year ago, and now those ones are stabilizing out. Part of that one was also our own selection on how we address the market. Now, little by little, the positives are coming. Markets are opening up.
Well-being counties are more and more capable of also buying and willing to buy. This market momentum is little by little turning. We have the consumer part that is growing. It is performing positively, and we will obviously continue to push on that part. Solid performance improvement in the portfolios when it comes to profitability. In Sweden, we are also improving both absolute EBIT and relative EBIT. We are still showing heftily negative numbers in a very, very seasonally low quarter. Q3 is always difficult and weak in Sweden due to how the offering behaves during vacation periods. What I'm really proud of is that our efficiency continues to ramp up. We continuously see on our KPIs positive development when it comes to occupancy rates, but also we start to see that one on the monthly gross margin levels going up.
We are now getting into an efficiency place, and we will load further volumes on top of that one. We have a solid sales pipeline that supports us getting back on track and on black numbers. The program is in plan. Improvements are now continuously more visible also in the backward-looking income statement, and we will then push forward. However, there is a weak market environment still in Sweden as a totality, so the macro has not recovered yet to the full extent. Despite macro, we are able to push Sweden back to good numbers in the coming year. If we look at our investments, we've been continuously investing in technology. We have been stating since the capital markets day last year that we will land somewhere between 4% - 5% of revenues in the longer perspective on the investments. Now we are at 3.4%. We are heavy in digital.
We have been talking about Ella, our professional user interface and related flows. You have seen during the quarter investments in MedHelp , the joint venture, which will be the digital front door in our occupational health. Some may have seen that we have deepened our collaboration with Gösta in the artificial intelligence and ambient scribing, further improving our tools. We have a good momentum. We have a solid technology roadmap, and we have the capability to invest, so we will continue doing on that one. In organic growth, the market is there, and we are evaluating different types of opportunities. For those opportunities, we had a solid quarter for cash flow. We are now in the green bucket again. As was the negative part, normal seasonality, so is this one. Our cash profile has not materially changed, and there's no reason to believe it materially changes either. Normal volatility.
We are the Swiss clock we have been. We tick, tick, tick cash. Our leverage ratios are 2.1 at the moment. We have fresh powder to continue investing. Positive financial position, and we can definitely do both organic and inorganic investments. If we look for our guidance, basically, this is unchanged. Despite some market headwinds, we reiterate our guidance after the second best third quarter ever. We are expecting our adjusted EBIT to be between EUR 155 million and EUR 165 million. These are based on the current demand environment, employment levels, and morbidity rates. Normal disclaimers, nothing new on that one. What is good to note may be that the implied range for Q4 seems highish compared to previous year Q4.
You need to look back on your notes and remember that in previous year Q4, we had especially personally related items that we don't have this quarter, this year in Q4. The baseline adjusting needs to be a bit taken to understand our Q4 performance. All in all, I'm happy to reiterate our guidance EUR 155 million - EUR 165 million in total. With these words, let's invite Kati on stage and let's have a Q&A.
Thanks, Juuso. I think we are ready to take questions from the phone lines.
If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Anssi Raussi from SEB. Please go ahead.
Yes, hi all, and thank you for the presentation. Maybe I start with your guidance, as you mentioned that as the last item here. You already said that there were some special items in your comparison period, but how should we think about, you know, underlying assumptions here, like does it require any improvement in the market sentiment or something you are not seeing yet to reach your lower end of the guidance range?
I think that's a very relevant question. At the moment, the guidance is based on the current market environment and the current morbidity rates. It already factors in, like always when issuing the guidance, everything we know up to yesterday evening. The current guidance assumes lowish morbidity rates and the occupational health market in the conditions we know at the moment.
Got it. That's clear then. Maybe the second question about your occupational health care. I think you said that maybe you lost some connected employees due to your profit improvement program. Do you think that it's possible to increase the number of employees or connected employees without sacrificing some of your profitability gains in this program?
Yeah, again, a good question. As I said during the presentation, it's not going to be either or. Either volume or profitability, it's going to be both going forward. It requires some balancing in our sort of offering and pricing, but we are not going to sacrifice the profitability just for the sake of absolute volume.
Okay, maybe continuing on that one. When we look at your, of course, you showed your appointment volumes and the impact of prices. How should we think about the pricing going forward in the coming quarters or years?
The cycle is very much different than it was, let's say, two, three years ago. The pressure on the contracts, pressure on prices is, of course, higher post-inflation cycle. You should not expect a sort of rapid price development going forward. Now it's more on how we package our products, what is the mix in our sort of agreement portfolio, and how efficient are we under the hood in delivering those services. The final component is the volume. The growth cannot be, for example, next year driven so much by the price increases, as we have seen during the past two years.
Okay, great. That's all from me. Thank you.
There are no more questions at this time, so I hand the conference back to the speakers.
All right. It's a busy results day today. I think there's some 30 companies today. There's one question in the webcast currently from DNB Carnegie from [Iris], two parts. Regarding the plan to address the revenue headwind, can we talk about when do we actually expect to see these measures become visible in the top line and whether we plan to provide any financial estimates of the sales or earnings impact of those actions?
If I start, like I actually hinted a bit or not even hinted, written out loud in the bridge that we would expect the connected employees' impact to be visible in 2026. That's obviously coming from the nature that if you today win something before it's visible and the connected employees are part of our portfolio, that especially in the big cases is a matter of months rather than anything else. We would expect in 2026 the impact. At the moment, obviously, our financial guidance relates to Q4 and full year 2025. We will come back for the total guidance for 2026 along with Q4 publication.
Yeah, again, the only caveat is with what Juuso said, this is that as I said before, we are not hunting the volume with the price of profitability. It is going to be both profitability and revenue and also volumes. We are not repeating the mistakes that the company did some six, seven, or five, six, seven years ago.
Maybe then continuing on that one, a follow-up question from [Iris]. We talked about an update to our product offering in the occupational health to make it more relevant for our customers. Can we give some examples on what that means in practical terms, and where do we expect to see the largest positive impact?
It's down to the segmentation of different needs amongst our customers. Of course, we are serving 30,000, roughly 30,000 different companies in Finland, and there's a wide spectrum of different types of needs and appetites also to pay for the services. Now, when we are talking about sort of transforming or renewing the products, typically it concerns the sort of customers who are more sort of keen on looking at the price and value for money type of comparisons. There we do have strong means inside the company to steer the services across our vast network. We have not used them to the full extent. What I mean is that if there's a company whose main focus is to get things to a certain level and then look at the spend after that one, we have means to serve that type of customer.
If there's a customer that wants to maximize the services to the employees, then we can serve that type of customer. If there's a product which is priced with a fixed contract, we have means to control both the profitability, delivery, and cost for that type of customers. That type of steering capabilities will be sort of utilized to full extent now going forward. We have the flexibility. We have different types of delivery models, and we are also renewing sort of commercial packaging of these types of different models.
Yeah, of course, MedHelp is a concrete example of the value increase that we can show to our customers in a relatively short term as well.
Absolutely, it's going to be next level.
Good. A question on the public outsourcing tenders and the outlook there. Besides the tender of Pirkanmaa Wellbeing Services County, which was won by our peer yesterday, are there any larger tenders opening up at the moment?
There is one other which we know of, and I think what's going to happen is that healthcare counties are watching very closely each other. When somebody is opening a path, the rest will follow, specifically if there's a successful implementation of a certain model. We believe that this is only a first step, this Pirha and concrete step Pihlajalinna for good competition and a nice win in there.
Yes, indeed. Maybe a question to both of you. Can we talk about the M&A pipeline? How does it look at the moment?
Yes, if I start. Basically, it is fair to say that M&A opportunities are now little by little emerging in different types of segments. We are, as we have said, happy to do disciplined M&A when we see an opportunity to fill a blank, whether it's a technology blank, offering blank, or other blank. That market is little by little activating, and we are, and we will be, active in that one.
Yes, just looking from sort of a short history perspective where we have been and where we are now and potentially will be. The activity on our desk is way higher than it has been for five years or so, five, six years. Sort of post-COVID or during COVID times, this is sort of an all-time high activity. There are real potentials out there. Of course, you always need to get over the sort of finish line to get something materialized. The funnel is there, and it's as strong as it's ever been during my term in Terveystalo.
Yeah, definitely signs of picking up there. A couple of questions from Matti Kaurala, OP. We mentioned that the insurance business is growing fast. Are there any possibilities to take more market share from other players in that segment?
It is not growing fast. It is growing steadily. The coverage of insurances in Finland has been developing positively, and the use of services has been developing positively. We have gained market share over the two last years. Further gaining market share, of course, requires also new means and new types of value creation for insurance companies. I think we have a strong plan there, which we continue implementing. The bigger moves, in my view, will happen only in 2027. Next year will be more like a steady progress in this segment.
Yes, of course, we have a clear attack plan for 2027 to deepen the cooperation with the insurance companies. Maybe continuing on the outsourcing market and the well-being services counties, how do we look at the public outsourcing market in general in the future? Is it attractive, and is it a part of our core offering and our business going forward?
We explicitly said earlier that we are interested in these new types of outsourcing deals. We were part of Pirha tender, and one can say looking now in hindsight, the competition and the outcome that each and every out of three main players were on the ball in sort of pricing and offering the package. Very close margins who won and who did not win. When it comes to profitability, of course, this would have not been sort of the richest agreement, but still value creating, EPS enhancing, which is the key for our business model. When these types of tenders come to the market, we are interested.
Indeed. At the moment, we don't... Oh, we have one more question from the phone lines. Let's take it now.
The next question comes from Anssi Raussi from SEB. Please go ahead.
Thanks. One follow-up from me. You mentioned these somewhat extraordinary costs last year in Q4, and there were some one-offs related to employee expenses. Can you remind us what kind of amount we are talking about, what you consider one-offs in Q4 last year?
Yes, so basically compared to baseline in last year, if you go into the details, you remember that we paid EUR 500 per employee to all employees, an extra bonus. Based on the CLA, there was EUR 500 per employee for all under CLA. That's the personal expenses I refer to. If you go into a bit deeper, you see that there was a bit of accelerated amortizations and depreciations in the income statement in Q4 last year. That one you need to put your finger into yourself, but normally forecasting depreciation and amortization is not super difficult.
Got it. Thank you.
Thanks. With that, I believe we don't have any further questions on the phone lines or from the webcast. Any closing words over to you, Ville?
As discussed earlier, a quarter of improving margins with revenue headwind, strong agenda to further accelerate the areas where we are progressing well and to tackle the headwind in occupational health investments with the dry powder provided by Juuso 's coffers, used more and more to digital offering where the agenda is strong. Architecture is there and delivering tangible results.
Great. With that, we thank you for your time and have a great rest of the week.
Thank you.
Thank you.